Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGS NASDAQ:APLM NASDAQ:MTEX NASDAQ:PPCB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$5.18-3.4%$6.96$5.12▼$13.69$33.17M2.28154,209 shs111,327 shsAPLMApollomics$14.36-4.3%$15.83$3.66▼$42.12$32.94M1.535,350 shs15,767 shsMTEXMannatech$4.21+2.2%$5.62$3.89▼$12.45$7.95M0.6151,086 shs19,477 shsPPCBPropanc Biopharma$2.01-2.0%$2.73$1.56▼$270.25$1.30M3.5959,119 shs160,538 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics-3.36%-19.94%-22.46%-23.82%-12.05%APLMApollomics-1.66%+0.17%+1.09%-29.29%+165.83%MTEXMannatech+2.18%-13.91%-19.04%-40.70%-57.60%PPCBPropanc Biopharma-1.95%-11.16%-28.02%-61.71%-97.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$5.18-3.4%$6.96$5.12▼$13.69$33.17M2.28154,209 shs111,327 shsAPLMApollomics$14.36-4.3%$15.83$3.66▼$42.12$32.94M1.535,350 shs15,767 shsMTEXMannatech$4.21+2.2%$5.62$3.89▼$12.45$7.95M0.6151,086 shs19,477 shsPPCBPropanc Biopharma$2.01-2.0%$2.73$1.56▼$270.25$1.30M3.5959,119 shs160,538 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics-3.36%-19.94%-22.46%-23.82%-12.05%APLMApollomics-1.66%+0.17%+1.09%-29.29%+165.83%MTEXMannatech+2.18%-13.91%-19.04%-40.70%-57.60%PPCBPropanc Biopharma-1.95%-11.16%-28.02%-61.71%-97.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 2.80Moderate Buy$41.50701.16% UpsideAPLMApollomics 1.00SellN/AN/AMTEXMannatech 1.00SellN/AN/APPCBPropanc Biopharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest MTEX, ALGS, PPCB, and APLM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/1/2026PPCBPropanc Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/20/2026ALGSAligos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026APLMApollomics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/26/2026ALGSAligos Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/26/2026ALGSAligos Therapeutics Westpark CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.003/19/2026ALGSAligos Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.003/18/2026ALGSAligos Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/11/2026ALGSAligos Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.00(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$2.19M14.64N/AN/A$5.14 per share1.01APLMApollomics$8.50M3.72N/AN/A($2.89) per share-4.97MTEXMannatech$108.04M0.08N/AN/A($2.88) per share-1.46PPCBPropanc BiopharmaN/AN/AN/AN/A$15.49 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$24.19M-$8.69N/AN/AN/A-1,919.68%-139.47%-90.88%8/5/2026 (Estimated)APLMApollomics-$10.94MN/AN/AN/AN/AN/AN/AN/AN/AMTEXMannatech-$15.21M-$6.71N/AN/AN/A-11.97%-2,383.34%-40.24%N/APPCBPropanc Biopharma-$58.92M-$13.19N/AN/AN/AN/A-151.28%-109.53%N/ALatest MTEX, ALGS, PPCB, and APLM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q4 2025MTEXMannatechN/A$0.49N/A$0.49N/A$24.92 million5/7/2026Q1 2026ALGSAligos Therapeutics-$2.29-$2.21+$0.08-$2.21$0.25 million$2.83 million4/15/2026Q4 2025MTEXMannatechN/A-$5.94N/A-$5.94N/A$26.64 million3/5/2026Q4 2025ALGSAligos Therapeutics-$2.09-$1.91+$0.18-$1.91$0.27 million$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/AAPLMApollomicsN/AN/AN/AN/AN/AMTEXMannatechN/AN/A-100.00%N/AN/APPCBPropanc BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A2.562.56APLMApollomicsN/A0.960.96MTEXMannatech0.481.090.59PPCBPropanc BiopharmaN/A2.372.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%APLMApollomics19.13%MTEXMannatech12.98%PPCBPropanc BiopharmaN/AInsider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics7.80%APLMApollomicsN/AMTEXMannatech41.50%PPCBPropanc Biopharma28.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.19 million5.71 millionNo DataAPLMApollomics452.20 millionN/ANot OptionableMTEXMannatech2501.93 million1.13 millionNot OptionablePPCBPropanc Biopharma1630,000453,000Not OptionableMTEX, ALGS, PPCB, and APLM HeadlinesRecent News About These CompaniesPropanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer PatientsMay 19 at 8:45 AM | globenewswire.comPropanc Biopharma, Inc. Reports Q3 Financial Results and Key Corporate DevelopmentsMay 15, 2026 | quiverquant.comQPropanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 ResultsMay 15, 2026 | globenewswire.comPropanc Biopharma, Inc. Announces 1-for-25 Reverse Stock Split to Enhance Nasdaq ComplianceMay 13, 2026 | quiverquant.comQPropanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth PlansMay 13, 2026 | globenewswire.comPropanc Biopharma Inc.April 24, 2026 | barrons.comRosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCBApril 17, 2026 | businesswire.comRosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation - PPCBApril 16, 2026 | tmcnet.comRosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCBApril 16, 2026 | businesswire.comPropanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, SpainMarch 24, 2026 | globenewswire.comPropanc Biopharma, Inc.: Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme TherapyMarch 12, 2026 | finanznachrichten.dePropanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in ...March 12, 2026 | bakersfield.comBPropanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme TherapyMarch 12, 2026 | globenewswire.comPropanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human StudyMarch 10, 2026 | globenewswire.comPropanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic ModelsMarch 3, 2026 | markets.businessinsider.comPropanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic ModelsMarch 3, 2026 | globenewswire.comPropanc Biopharma, Inc.: Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 ResultsFebruary 18, 2026 | finanznachrichten.dePropanc Biopharma, Inc. Reports Half-Yearly Financial Results and Progress in Cancer Treatment DevelopmentFebruary 18, 2026 | quiverquant.comQPropanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 ResultsFebruary 18, 2026 | globenewswire.comPropanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer MarketFebruary 5, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTEX, ALGS, PPCB, and APLM Company DescriptionsAligos Therapeutics NASDAQ:ALGS$5.18 -0.18 (-3.36%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$5.38 +0.20 (+3.94%) As of 05/19/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Apollomics NASDAQ:APLM$14.36 -0.65 (-4.30%) Closing price 05/19/2026 03:58 PM EasternExtended Trading$14.36 0.00 (0.00%) As of 05/19/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.Mannatech NASDAQ:MTEX$4.21 +0.09 (+2.18%) As of 05/19/2026 03:53 PM EasternMannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.Propanc Biopharma NASDAQ:PPCB$2.01 -0.04 (-1.95%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$1.92 -0.09 (-4.48%) As of 05/19/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
